Current Landscape of Gene Therapy for the Treatment of Cardiovascular
Disorders

Pranay      Wal; Namra      Aziz; Chetan   Pratap   Singh; Azhar      Rasheed; Lalit   Kumar   Tyagi; Ankur      Agrawal; Ankita      Wal
Abstract

Cardiovascular disorders (CVD) are the primary cause of death worldwide. Multiple factors have been accepted to cause cardiovascular diseases; among them, smoking, physical inactivity, unhealthy eating habits, age, and family history are flag-bearers. Individuals at risk of developing CVD are suggested to make drastic habitual changes as the primary intervention to prevent CVD; however, over time, the disease is bound to worsen. This is when secondary interventions come into play, including antihypertensive, anti-lipidemic, anti-anginal, and inotropic drugs. These drugs usually undergo surgical intervention in patients with a much higher risk of heart failure. These therapeutic agents increase the survival rate, decrease the severity of symptoms and the discomfort that comes with them, and increase the overall quality of life. However, most individuals succumb to this disease. None of these treatments address the molecular mechanism of the disease and hence are unable to halt the pathological worsening of the disease. Gene therapy offers a more efficient, potent, and important novel approach to counter the disease, as it has the potential to permanently eradicate the disease from the patients and even in the upcoming generations. However, this therapy is associated with significant risks and ethical considerations that pose noteworthy resistance. In this review, we discuss various methods of gene therapy for cardiovascular disorders and address the ethical conundrum surrounding it.
Keywords: Gene, vectors, non-viral vector, gene therapy, gene editing technology, cardiovascular disorder.
Graphical Abstract

[1]
Lopez E, Ballard BD, Jan A. Cardiovascular disease. StatPearls. Treasure Island, FL: StatPearls Publishing 2023. https:// www.ncbi.nlm.nih.gov/books/NBK535419/ Updated 2023 Aug 7 Internet

[2]
World health statistics 2023: Monitoring health for the SDGs, Sustainable Development Goals. Geneva: World health organization; 2023. licence. 2023. Available from:  https://www.who.int/publications/i/item/9789240074323

[3]
Indian Heart Association.  Available from:  https://indianheartassociation.org/why-indians-why-south-asians/#:~:text=Public%20health%20estimates%20indicate%20that,a%20silent%20epidemic%20among%20Indians

[4]
Liew LC, Ho BX, Soh BS. Mending a broken heart: Current strategies and limitations of cell-based therapy. Stem Cell Res Ther  2020; 11(1): 138.
 [http://dx.doi.org/10.1186/s13287-020-01648-0] [PMID: 32216837]

[5]
Khakoo AY, Yurgin NR, Eisenberg PR, Fonarow GC. Overcoming barriers to development of novel therapies for cardiovascular disease: Insights from the oncology drug development experience. JACC Basic Transl Sci  2019; 4(2): 269-74.
 [http://dx.doi.org/10.1016/j.jacbts.2019.01.011] [PMID: 31061928]

[6]
Gonçalves GAR, Paiva RMA. Gene therapy: Advances, challenges and perspectives. Einstein  2017; 15(3): 369-75.
 [http://dx.doi.org/10.1590/s1679-45082017rb4024] [PMID: 29091160]

[7]
Hajjar RJ. Potential of gene therapy as a treatment for heart failure. J Clin Invest  2013; 123(1): 53-61.
 [http://dx.doi.org/10.1172/JCI62837] [PMID: 23281410]

[8]
 Nóbrega C, Mendonça L, Matos CA. A handbook of gene and cell therapy. Basel, Switzerland: Springer 2020.
 [http://dx.doi.org/10.1007/978-3-030-41333-0]

[9]
Ahmed A, Saadi H. Gene therapy approaches. Qubahan Academic Journal  2021; 1(1): 52-6.
 [http://dx.doi.org/10.48161/qaj.v1n1a35]

[10]
Ormond KE, Mortlock DP, Scholes DT, et al. Human germline genome editing. Am J Hum Genet  2017; 101(2): 167-76.
 [http://dx.doi.org/10.1016/j.ajhg.2017.06.012] [PMID: 28777929]

[11]
Wolf DP, Mitalipov PA, Mitalipov SM. Principles of and strategies for germline gene therapy. Nat Med  2019; 25(6): 890-7.
 [http://dx.doi.org/10.1038/s41591-019-0473-8] [PMID: 31160821]

[12]
Kim Y, Zharkinbekov Z, Sarsenova M, Yeltay G, Saparov A. Recent advances in gene therapy for cardiac tissue regeneration. Int J Mol Sci  2021; 22(17): 9206.
 [http://dx.doi.org/10.3390/ijms22179206]

[13]
Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. Gene  2014; 538(2): 217-27.
 [http://dx.doi.org/10.1016/j.gene.2013.12.019] [PMID: 24406620]

[14]
Sibley CR, Seow Y, Wood MJA. Novel RNA-based strategies for therapeutic gene silencing. Mol Ther  2010; 18(3): 466-76.
 [http://dx.doi.org/10.1038/mt.2009.306] [PMID: 20087319]

[15]
Navarro SA, Carrillo E, Griñán-Lisón C, et al. Cancer suicide gene therapy: A patent review. Expert Opin Ther Pat  2016; 26(9): 1095-104.
 [http://dx.doi.org/10.1080/13543776.2016.1211640] [PMID: 27424657]

[16]
Your Genome.  Available from: https://www.yourgenome.org/facts/what-is-gene-therapy/ (Accessed Nov 15, 2023).

[17]
Petrich J, Marchese D, Jenkins C, Storey M, Blind J. Gene replacement therapy: A primer for the health-system pharmacist. J Pharm Pract  2020; 33(6): 846-55.
 [http://dx.doi.org/10.1177/0897190019854962] [PMID: 31248331]

[18]
Wang D, Gao G. State-of-the-art human gene therapy: Part II. Gene therapy strategies and clinical applications. Discov Med  2014; 18(98): 151-61.
 [PMID: 25227756]

[19]
Cao G, Xuan X, Zhang R, Hu J, Dong H. Gene therapy for cardiovascular disease: Basic research and clinical prospects. Front Cardiovasc Med  2021; 8: 760140.
 [http://dx.doi.org/10.3389/fcvm.2021.760140] [PMID: 34805315]

[20]
Musunuru K. Moving toward genome-editing therapies for cardiovascular diseases. J Clin Invest  2022; 132(1): e148555.
 [http://dx.doi.org/10.1172/JCI148555] [PMID: 34981785]

[21]
Khan SH. Genome-editing technologies: Concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application. Mol Ther Nucleic Acids  2019; 16: 326-34.
 [http://dx.doi.org/10.1016/j.omtn.2019.02.027] [PMID: 30965277]

[22]
Chadwick AC, Musunuru K. Genome editing for the study of cardiovascular diseases. Curr Cardiol Rep  2017; 19(3): 22.
 [http://dx.doi.org/10.1007/s11886-017-0830-5] [PMID: 28220462]

[23]
Germini D, Tsfasman T, Zakharova VV, Sjakste N, Lipinski M, Vassetzky Y. A comparison of techniques to evaluate the effectiveness of genome editing. Trends Biotechnol  2018; 36(2): 147-59.
 [http://dx.doi.org/10.1016/j.tibtech.2017.10.008] [PMID: 29157536]

[24]
Gaj T, Sirk SJ, Shui S, Liu J. Genome-editing technologies: Principles and applications. Cold Spring Harb Perspect Biol  2016; 8(12): a023754.
 [http://dx.doi.org/10.1101/cshperspect.a023754] [PMID: 27908936]

[25]
Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther  2016; 24(3): 430-46.
 [http://dx.doi.org/10.1038/mt.2016.10] [PMID: 26755333]

[26]
Khalil AM. The genome editing revolution: Review. J Genet Eng Biotechnol  2020; 18(1): 68.
 [http://dx.doi.org/10.1186/s43141-020-00078-y] [PMID: 33123803]

[27]
Aravalli RN, Steer CJ. Gene editing technology as an approach to the treatment of liver diseases. Expert Opin Biol Ther  2016; 16(5): 595-608.
 [http://dx.doi.org/10.1517/14712598.2016.1158808] [PMID: 26914853]

[28]
Rahim J, Gulzar S, Zahid R, Rahim KA. A systematic review on the comparison of molecular gene editing tools. Int J Innov Sci Res Tech  2021; 6: 1-8.

[29]
Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. Signal Transduct Target Ther  2020; 5(1): 1.
 [http://dx.doi.org/10.1038/s41392-019-0089-y] [PMID: 32296011]

[30]
Chandrasegaran S, Carroll D. Origins of programmable nucleases for genome engineering. J Mol Biol  2016; 428(5): 963-89.
 [http://dx.doi.org/10.1016/j.jmb.2015.10.014] [PMID: 26506267]

[31]
Bogdanove AJ, Voytas DF. TAL effectors: Customizable proteins for DNA targeting. Science  2011; 333(6051): 1843-6.
 [http://dx.doi.org/10.1126/science.1204094] [PMID: 21960622]

[32]
Boch J, Bonas U. Xanthomonas AvrBs3 family-type III effectors: Discovery and function. Annu Rev Phytopathol  2010; 48(1): 419-36.
 [http://dx.doi.org/10.1146/annurev-phyto-080508-081936] [PMID: 19400638]

[33]
Kim MS, Kini AG. Engineering and application of zinc finger proteins and TALEs for biomedical research. Mol Cells  2017; 40(8): 533-41.
 [http://dx.doi.org/10.14348/molcells.2017.0139] [PMID: 28835021]

[34]
Bultmann S, Morbitzer R, Schmidt CS, et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res  2012; 40(12): 5368-77.
 [http://dx.doi.org/10.1093/nar/gks199] [PMID: 22387464]

[35]
Holkers M, Maggio I, Liu J, et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res  2013; 41(5): e63.
 [http://dx.doi.org/10.1093/nar/gks1446] [PMID: 23275534]

[36]
Li T, Huang S, Jiang WZ, et al. TAL nucleases (TALNs): Hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res  2011; 39(1): 359-72.
 [http://dx.doi.org/10.1093/nar/gkq704] [PMID: 20699274]

[37]
Joung JK, Sander JD. TALENs: A widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol  2013; 14(1): 49-55.
 [http://dx.doi.org/10.1038/nrm3486] [PMID: 23169466]

[38]
Walker HE, Rizzo M, Fras Z, Jug B, Banach M, Penson PE. CRISPR gene editing in lipid disorders and atherosclerosis: Mechanisms and opportunities. Metabolites  2021; 11(12): 857.
 [http://dx.doi.org/10.3390/metabo11120857] [PMID: 34940615]

[39]
Singh V, Braddick D, Dhar PK. Exploring the potential of genome editing CRISPR-Cas9 technology. Gene  2017; 599: 1-18.
 [http://dx.doi.org/10.1016/j.gene.2016.11.008] [PMID: 27836667]

[40]
Amitai G, Sorek R. CRISPR–Cas adaptation: Insights into the mechanism of action. Nat Rev Microbiol  2016; 14(2): 67-76.
 [http://dx.doi.org/10.1038/nrmicro.2015.14] [PMID: 26751509]

[41]
Nguyen Q, Lim KRQ, Yokota T. Genome editing for the understanding and treatment of inherited cardiomyopathies. Int J Mol Sci  2020; 21(3): 733.
 [http://dx.doi.org/10.3390/ijms21030733] [PMID: 31979133]

[42]
Roshanravan N, Tutunchi H, Najafipour F, Dastouri M, Ghaffari S, Jebeli A. A glance at the application of CRISPR/Cas9 gene-editing technology in cardiovascular diseases. J Cardiovasc Thorac Res  2022; 14(2): 77-83.
 [http://dx.doi.org/10.34172/jcvtr.2022.14] [PMID: 35935390]

[43]
Khouzam JPS, Tivakaran VS. CRISPR-Cas9 applications in cardiovascular disease. Curr Probl Cardiol  2021; 46(3): 100652.
 [http://dx.doi.org/10.1016/j.cpcardiol.2020.100652] [PMID: 32828559]

[44]
Mani I. Genome editing in cardiovascular diseases. Prog Mol Biol Transl Sci  2021; 181: 289-308.
 [http://dx.doi.org/10.1016/bs.pmbts.2021.01.021] [PMID: 34127197]

[45]
Vermersch E, Jouve C, Hulot JS. CRISPR/Cas9 gene-editing strategies in cardiovascular cells. Cardiovasc Res  2020; 116(5): 894-907.
 [http://dx.doi.org/10.1093/cvr/cvz250] [PMID: 31584620]

[46]
Chakraborty S. A glance at genome editing with CRISPR Cas9 technology. Springer Nature 2019.

[47]
Musunuru K. The hope and hype of CRISPR-Cas9 genome editing: a review. JAMA Cardiol  2017; 2(8): 914-9.
 [http://dx.doi.org/10.1001/jamacardio.2017.1713] [PMID: 28614576]

[48]
Ganipineni VDP, Gutlapalli SD, Danda S, et al. Clustered regularly interspaced short palindromic repeats (CRISPR) in cardiovascular disease: A comprehensive clinical review on dilated cardiomyopathy. Cureus  2023; 15(3): e35774.
 [http://dx.doi.org/10.7759/cureus.35774] [PMID: 37025725]

[49]
Alhakamy NA, Curiel DT, Berkland CJ. The era of gene therapy: From preclinical development to clinical application. Drug Discov Today  2021; 26(7): 1602-19.
 [http://dx.doi.org/10.1016/j.drudis.2021.03.021] [PMID: 33781953]

[50]
Akram F, Sahreen S, Aamir F, et al. An insight into modern targeted genome-editing technologies with a special focus on CRISPR/Cas9 and its applications. Mol Biotechnol  2023; 65(2): 227-42.
 [http://dx.doi.org/10.1007/s12033-022-00501-4] [PMID: 35474409]

[51]
Mak MCE, Gurung R, Foo RSY. Applications of genome editing technologies in CAD research and therapy with a focus on atherosclerosis. Int J Mol Sci  2023; 24(18): 14057.
 [http://dx.doi.org/10.3390/ijms241814057] [PMID: 37762360]

[52]
Tamura R, Toda M. Historic overview of genetic engineering technologies for human gene therapy. Neurol Med Chir  2020; 60(10): 483-91.
 [http://dx.doi.org/10.2176/nmc.ra.2020-0049] [PMID: 32908085]

[53]
Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med  2014; 370(10): 901-10.
 [http://dx.doi.org/10.1056/NEJMoa1300662] [PMID: 24597865]

[54]
Strong A, Musunuru K. Genome editing in cardiovascular diseases. Nat Rev Cardiol  2017; 14(1): 11-20.
 [http://dx.doi.org/10.1038/nrcardio.2016.139] [PMID: 27609628]

[55]
Mussolino C, Alzubi J, Fine EJ, et al. TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res  2014; 42(10): 6762-73.
 [http://dx.doi.org/10.1093/nar/gku305] [PMID: 24792154]

[56]
Hernandez-Benitez R, Martinez-Martinez ML, Lajara J, Magistretti P, Montserrat N, Belmonte JC. At the heart of genome editing and cardiovascular diseases. Circ Res  2018; 123(2): 221-3.
 [http://dx.doi.org/10.1161/CIRCRESAHA.118.312676] [PMID: 29976689]

[57]
Karakikes I, Termglinchan V, Cepeda DA, et al. A comprehensive TALEN-based knockout library for generating human-induced pluripotent stem cell–based models for cardiovascular diseases. Circ Res  2017; 120(10): 1561-71.
 [http://dx.doi.org/10.1161/CIRCRESAHA.116.309948] [PMID: 28246128]

[58]
Rezaei H, khadempar S, Farahani N, et al. Harnessing CRISPR/Cas9 technology in cardiovascular disease. Trends Cardiovasc Med  2020; 30(2): 93-101.
 [http://dx.doi.org/10.1016/j.tcm.2019.03.005] [PMID: 30935726]

[59]
Li ZH, Wang J, Xu JP, Wang J, Yang X. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research. Mil Med Res  2023; 10(1): 12.
 [http://dx.doi.org/10.1186/s40779-023-00447-x] [PMID: 36895064]

[60]
Lee CM, Cradick TJ, Fine EJ, Bao G. Nuclease target site selection for maximizing on-target activity and minimizing off-target effects in genome editing. Mol Ther  2016; 24(3): 475-87.
 [http://dx.doi.org/10.1038/mt.2016.1] [PMID: 26750397]

[61]
Musunuru K. Genome editing. J Am Coll Cardiol  2017; 70(22): 2808-21.
 [http://dx.doi.org/10.1016/j.jacc.2017.10.002] [PMID: 29191331]

[62]
Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res  2015; 9(1): GE01-6.
 [http://dx.doi.org/10.7860/JCDR/2015/10443.5394] [PMID: 25738007]

[63]
Laakkonen JP, Ylä-Herttuala S. Recent advancements in cardiovascular gene therapy and vascular biology. Hum Gene Ther  2015; 26(8): 518-24.
 [http://dx.doi.org/10.1089/hum.2015.095] [PMID: 26192706]

[64]
Katz MG, Fargnoli AS, Williams RD, Bridges CR. Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: Current concepts and future applications. Hum Gene Ther  2013; 24(11): 914-27.
 [http://dx.doi.org/10.1089/hum.2013.2517] [PMID: 24164239]

[65]
Katz MG, Fargnoli AS, Kendle AP, Bridges CR. Gene therapy in cardiovascular disease.  In: Pathophysiology and Pharmacotherapy of Cardiovascular Disease 2015; pp. 265-87.

[66]
Zhao Z, Anselmo AC, Mitragotri S. Viral vector-based gene therapies in the clinic. Bioeng Transl Med  2022; 7(1): e10258.
 [http://dx.doi.org/10.1002/btm2.10258] [PMID: 35079633]

[67]
 Weber T, Zangi L, Hajjar RJ. Gene therapy for cardiovascular diseases. In: Stem cell and gene therapy for cardiovascular disease. Academic Press 2016; pp. 377-87.

[68]
Wang D, Gao G. State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med  2014; 18(97): 67-77.
 [PMID: 25091489]

[69]
Mali S. Delivery systems for gene therapy. Indian J Hum Genet  2013; 19(1): 3-8.
 [http://dx.doi.org/10.4103/0971-6866.112870] [PMID: 23901186]

[70]
 Reyes-Juárez JL, Zarain-Herzberg A. Gene therapy in cardiovascular disease. Gene Therapy Applications. InTech 2011; pp. 95-126.

[71]
Hardee C, Arévalo-Soliz L, Hornstein B, Zechiedrich L. Advances in non-viral DNA vectors for gene therapy. Genes  2017; 8(2): 65.
 [http://dx.doi.org/10.3390/genes8020065] [PMID: 28208635]

[72]
Hosseinkhani H, Domb AJ, Sharifzadeh G, Nahum V. Gene therapy for regenerative medicine. Pharmaceutics  2023; 15(3): 856.
 [http://dx.doi.org/10.3390/pharmaceutics15030856] [PMID: 36986717]

[73]
Williams PD, Kingston PA. Plasmid-mediated gene therapy for cardiovascular disease. Cardiovasc Res  2011; 91(4): 565-76.
 [http://dx.doi.org/10.1093/cvr/cvr197] [PMID: 21742674]

[74]
Rincon MY, VandenDriessche T, Chuah MK. Gene therapy for cardiovascular disease: Advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res  2015; 108(1): 4-20.
 [http://dx.doi.org/10.1093/cvr/cvv205] [PMID: 26239654]

[75]
Hurley A, Lagor WR. Treating cardiovascular disease with liver genome engineering. Curr Atheroscler Rep  2022; 24(2): 75-84.
 [http://dx.doi.org/10.1007/s11883-022-00986-z] [PMID: 35230602]

[76]
Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet  2022; 23(5): 265-80.
 [http://dx.doi.org/10.1038/s41576-021-00439-4] [PMID: 34983972]

[77]
Katzmann JL, Cupido AJ, Laufs U. Gene therapy targeting PCSK9. Metabolites  2022; 12(1): 70.
 [http://dx.doi.org/10.3390/metabo12010070] [PMID: 35050192]

[78]
Soumya RS, Raghu KG. Recent advances on nanoparticle-based therapies for cardiovascular diseases. J Cardiol  2023; 81(1): 10-8.
 [http://dx.doi.org/10.1016/j.jjcc.2022.02.009] [PMID: 35210166]

[79]
Lundstrom K. Viral vectors in gene therapy. Diseases  2018; 6(2): 42.
 [http://dx.doi.org/10.3390/diseases6020042] [PMID: 29883422]

[80]
Ghosh S, Brown AM, Jenkins C, Campbell K. Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges. Appl Biosaf  2020; 25(1): 7-18.
 [http://dx.doi.org/10.1177/1535676019899502] [PMID: 36033383]

[81]
Lähteenvuo J, Ylä-Herttuala S. Advances and challenges in cardiovascular gene therapy. Hum Gene Ther  2017; 28(11): 1024-32.
 [http://dx.doi.org/10.1089/hum.2017.129] [PMID: 28810808]

[82]
Chen C, Seeger T, Termglinchan V, Karakikes I. Recent advances in cardiac gene therapy strategies targeting advanced heart failure. Contin Cardiol Educ  2017; 3(4): 163-9.
 [http://dx.doi.org/10.1002/cce2.68]

[83]
Jt S, M H, Wam B, Ac B, Sa N. Adenoviral vectors for cardiovascular gene therapy applications: A clinical and industry perspective. J Mol Med  2022; 100(6): 875-901.
 [http://dx.doi.org/10.1007/s00109-022-02208-0] [PMID: 35606652]

[84]
Lee CS, Bishop ES, Zhang R, et al. Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis  2017; 4(2): 43-63.
 [http://dx.doi.org/10.1016/j.gendis.2017.04.001] [PMID: 28944281]

[85]
Matsunaga W, Gotoh A. Adenovirus as a vector and oncolytic virus. Curr Issues Mol Biol  2023; 45(6): 4826-40.
 [http://dx.doi.org/10.3390/cimb45060307] [PMID: 37367056]

[86]
Zhang H, Wang H, An Y, Chen Z. Construction and application of adenoviral vectors. Mol Ther Nucleic Acids  2023; 34: 102027.
 [http://dx.doi.org/10.1016/j.omtn.2023.09.004] [PMID: 37808925]

[87]
Alonso-Padilla J, Papp T, Kaján GL, et al. Development of novel adenoviral vectors to overcome challenges observed with HAdV-5–based constructs. Mol Ther  2016; 24(1): 6-16.
 [http://dx.doi.org/10.1038/mt.2015.194] [PMID: 26478249]

[88]
Singh S, Kumar R, Agrawal B. Adenoviral vector-based vaccines and gene therapies: Current status and future prospects. Adenoviruses  2019; 4: 53-91.
 [http://dx.doi.org/10.5772/intechopen.79697]

[89]
Lundstrom K. Viral vectors in gene therapy: Where do we stand in 2023? Viruses  2023; 15(3): 698.
 [http://dx.doi.org/10.3390/v15030698] [PMID: 36992407]

[90]
Syyam A, Nawaz A, Ijaz A, et al. Adenovirus vector system: Construction, history and therapeutic applications. Biotechniques  2022; 73(6): 297-305.
 [http://dx.doi.org/10.2144/btn-2022-0051] [PMID: 36475496]

[91]
Balakrishnan B, Jayandharan G. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther  2014; 14(2): 86-100.
 [http://dx.doi.org/10.2174/1566523214666140302193709] [PMID: 24588706]

[92]
Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol  2014; 1(1): 427-51.
 [http://dx.doi.org/10.1146/annurev-virology-031413-085355] [PMID: 26958729]

[93]
Asokan A, Samulski RJ. An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum Gene Ther  2013; 24(11): 906-13.
 [http://dx.doi.org/10.1089/hum.2013.2515] [PMID: 24164238]

[94]
Zacchigna S, Zentilin L, Giacca M. Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circ Res  2014; 114(11): 1827-46.
 [http://dx.doi.org/10.1161/CIRCRESAHA.114.302331] [PMID: 24855205]

[95]
Chen H. Adeno-associated virus vectors for human gene therapy. World J Med Genet  2015; 5(3): 28-45.
 [http://dx.doi.org/10.5496/wjmg.v5.i3.28]

[96]
Zhang H, Zhan Q, Huang B, Wang Y, Wang X. AAV-mediated gene therapy: Advancing cardiovascular disease treatment. Front Cardiovasc Med  2022; 9: 952755.
 [http://dx.doi.org/10.3389/fcvm.2022.952755] [PMID: 36061546]

[97]
Mancini D, Farr MJ. Gene therapy for heart failure: An investigational treatment that is coming of age. Rev Esp Cardiol  2010; 63(2): 137-40.
 [http://dx.doi.org/10.1016/S0300-8932(10)70030-0] [PMID: 20109411]

[98]
Zinn E, Vandenberghe LH. Adeno-associated virus: Fit to serve. Curr Opin Virol  2014; 8: 90-7.
 [http://dx.doi.org/10.1016/j.coviro.2014.07.008] [PMID: 25128609]

[99]
Gorabi AM, Hajighasemi S, Tafti HA, et al. Gene therapy in cardiovascular diseases: A review of recent updates. J Cell Biochem  2018; 119(12): 9645-54.
 [http://dx.doi.org/10.1002/jcb.27303] [PMID: 30129172]

[100]
Hayward A. Origin of the retroviruses: When, where, and how? Curr Opin Virol  2017; 25: 23-7.
 [http://dx.doi.org/10.1016/j.coviro.2017.06.006] [PMID: 28672160]

[101]
Yi Y, Noh M, Lee K. Current advances in retroviral gene therapy. Curr Gene Ther  2011; 11(3): 218-28.
 [http://dx.doi.org/10.2174/156652311795684740] [PMID: 21453283]

[102]
Advani U, Bansal A, Prakash R, Agarwal S. Gene therapy and its applications. J Med Evid  2023; 4(1): 46-56.
 [http://dx.doi.org/10.4103/JME.JME_65_21]

[103]
Matuskova M, Durinikova E. Retroviral vectors in gene therapy. Adv Mol Retrovirol 2016.

[104]
Gopinath C, Nathar TJ, Nelson EJ. Retroviral vectors in gene therapy. Gene and Cell Therapy: Biology and Applications  2018; 3-28.

[105]
Li X, Le Y, Zhang Z, Nian X, Liu B, Yang X. Viral vector-based gene therapy. Int J Mol Sci  2023; 24(9): 7736.
 [http://dx.doi.org/10.3390/ijms24097736] [PMID: 37175441]

[106]
Cavalieri V, Baiamonte E, Lo Iacono M. Non-primate lentiviral vectors and their applications in gene therapy for ocular disorders. Viruses  2018; 10(6): 316.
 [http://dx.doi.org/10.3390/v10060316] [PMID: 29890733]

[107]
Young GR, Stoye JP, Kassiotis G. Are human endogenous retroviruses pathogenic? An approach to testing the hypothesis. BioEssays  2013; 35(9): 794-803.
 [http://dx.doi.org/10.1002/bies.201300049] [PMID: 23864388]

[108]
Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature  2014; 510(7504): 235-40.
 [http://dx.doi.org/10.1038/nature13420] [PMID: 24870228]

[109]
Mamcarz E, Zhou S, Lockey T, et al. Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1. N Engl J Med  2019; 380(16): 1525-34.
 [http://dx.doi.org/10.1056/NEJMoa1815408] [PMID: 30995372]

[110]
Nayak S, Herzog RW. Progress and prospects: Immune responses to viral vectors. Gene Ther  2010; 17(3): 295-304.
 [http://dx.doi.org/10.1038/gt.2009.148] [PMID: 19907498]

[111]
Papayannakos C, Daniel R. Understanding lentiviral vector chromatin targeting: Working to reduce insertional mutagenic potential for gene therapy. Gene Ther  2013; 20(6): 581-8.
 [http://dx.doi.org/10.1038/gt.2012.88] [PMID: 23171920]

[112]
Manservigi R, Argnani R, Marconi P. HSV recombinant vectors for gene therapy. Open Virol J  2010; 4: 123-56.
 [PMID: 20835362]

[113]
Miyagawa Y, Marino P, Verlengia G, et al. Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. Proc Natl Acad Sci  2015; 112(13): E1632-41.
 [http://dx.doi.org/10.1073/pnas.1423556112] [PMID: 25775541]

[114]
Goswami R, Subramanian G, Silayeva L, et al. Gene therapy leaves a vicious cycle. Front Oncol  2019; 9: 297.
 [http://dx.doi.org/10.3389/fonc.2019.00297] [PMID: 31069169]

[115]
Khan KH. Gene transfer technologies and their applications: Roles in human diseases. Asian J Exp Biol Sci  2010; 1(2): 208-18.

[116]
Horii T, Arai Y, Yamazaki M, et al. Validation of microinjection methods for generating knockout mice by CRISPR/Cas-mediated genome engineering. Sci Rep  2014; 4(1): 4513.
 [http://dx.doi.org/10.1038/srep04513] [PMID: 24675426]

[117]
Young JL, Dean DA. Electroporation-mediated gene delivery. Adv Genet  2015; 89: 49-88.
 [http://dx.doi.org/10.1016/bs.adgen.2014.10.003] [PMID: 25620008]

[118]
Potter H, Heller R. Transfection by electroporation. Curr Protoc Immunol  2017; 117(1): 15.1-, 9.
 [http://dx.doi.org/10.1002/cpim.24] [PMID: 28369680]

[119]
Ayuni EL, Gazdhar A, Giraud MN, et al. In vivo electroporation mediated gene delivery to the beating heart. PLoS One  2010; 5(12): e14467.
 [http://dx.doi.org/10.1371/journal.pone.0014467] [PMID: 21209934]

[120]
 Gascón AR, del Pozo-Rodríguez A, Solinís MÁ. Non-viral delivery systems in gene therapy. In Gene therapy-tools and potential applications. IntechOpen 2013.

[121]
Su CH, Wu YJ, Wang HH, Yeh HI. Nonviral gene therapy targeting cardiovascular system. Am J Physiol Heart Circ Physiol  2012; 303(6): H629-38.
 [http://dx.doi.org/10.1152/ajpheart.00126.2012] [PMID: 22821991]

[122]
Sharma D, Arora S, Singh J, Layek B. A review of the tortuous path of nonviral gene delivery and recent progress. Int J Biol Macromol  2021; 183: 2055-73.
 [http://dx.doi.org/10.1016/j.ijbiomac.2021.05.192] [PMID: 34087309]

[123]
Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Sonoporation: Gene transfer using ultrasound. World J Methodol  2013; 3(4): 39-44.
 [http://dx.doi.org/10.5662/wjm.v3.i4.39] [PMID: 25237622]

[124]
Castle J, Feinstein SB. Drug and gene delivery using sonoporation for cardiovascular disease.  Therapeutic Ultrasound 2016; pp. 331-8.
 [http://dx.doi.org/10.1007/978-3-319-22536-4_18]

[125]
Yang Y, Li Q, Guo X, Tu J, Zhang D. Mechanisms underlying sonoporation: Interaction between microbubbles and cells. Ultrason Sonochem  2020; 67: 105096.
 [http://dx.doi.org/10.1016/j.ultsonch.2020.105096] [PMID: 32278246]

[126]
Delalande A, Postema M, Mignet N, Midoux P, Pichon C. Ultrasound and microbubble-assisted gene delivery: Recent advances and ongoing challenges. Ther Deliv  2012; 3(10): 1199-215.
 [http://dx.doi.org/10.4155/tde.12.100] [PMID: 23116012]

[127]
Sutton JT, Haworth KJ, Pyne-Geithman G, Holland CK. Ultrasound-mediated drug delivery for cardiovascular disease. Expert Opin Drug Deliv  2013; 10(5): 573-92.
 [http://dx.doi.org/10.1517/17425247.2013.772578] [PMID: 23448121]

[128]
Chen HH, Matkar PN, Afrasiabi K, Kuliszewski MA, Leong-Poi H. Prospect of ultrasound-mediated gene delivery in cardiovascular applications. Expert Opin Biol Ther  2016; 16(6): 815-26.
 [http://dx.doi.org/10.1517/14712598.2016.1169268] [PMID: 27063021]

[129]
Estelrich J, Escribano E, Queralt J, Busquets M. Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci  2015; 16(12): 8070-101.
 [http://dx.doi.org/10.3390/ijms16048070] [PMID: 25867479]

[130]
Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomaterials research  2019; 23: 1-7.
 [http://dx.doi.org/10.1186/s40824-019-0156-z]

[131]
 Crespo-Barreda A, Encabo-Berzosa MM, González-Pastor R, et al. Viral and nonviral vectors for in vivo and ex vivo gene therapies. Translating Regenerative Medicine to the Clinic 2016; pp. 155-77.
 [http://dx.doi.org/10.1016/B978-0-12-800548-4.00011-5]

[132]
Schwerdt JI, Goya GF, Calatayud MP, Hereñú CB, Reggiani PC, Goya RG. Magnetic field-assisted gene delivery: Achievements and therapeutic potential. Curr Gene Ther  2012; 12(2): 116-26.
 [http://dx.doi.org/10.2174/156652312800099616] [PMID: 22348552]

[133]
 Herrero MJ, Sendra L, Miguel A, Aliño SF. Physical methods of gene delivery. Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders 2017; pp. 113-35.

[134]
Di Mauro V, Iafisco M, Salvarani N, et al. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs. Nanomedicine  2016; 11(8): 891-906.
 [http://dx.doi.org/10.2217/nnm.16.26] [PMID: 26979495]

[135]
Fus-Kujawa A, Prus P, Bajdak-Rusinek K, et al. An overview of methods and tools for transfection of eukaryotic cells in vitro. Front Bioeng Biotechnol  2021; 9: 701031.
 [http://dx.doi.org/10.3389/fbioe.2021.701031] [PMID: 34354988]

[136]
Hirata M, Wittayarat M, Namula Z, et al. Lipofection-mediated introduction of CRISPR/Cas9 system into porcine oocytes and embryos. Animals  2021; 11(2): 578.
 [http://dx.doi.org/10.3390/ani11020578] [PMID: 33672168]

[137]
Mathiyalagan P, Sahoo S. Exosomes-based gene therapy for microRNA delivery. Cardiac gene therapy: Methods and protocols  2017; 139-52.

[138]
Xitong D, Xiaorong Z. Targeted therapeutic delivery using engineered exosomes and its applications in cardiovascular diseases. Gene  2016; 575(2): 377-84.
 [http://dx.doi.org/10.1016/j.gene.2015.08.067] [PMID: 26341056]

[139]
Baek G, Choi H, Kim Y, Lee HC, Choi C. Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform. Stem Cells Transl Med  2019; 8(9): 880-6.
 [http://dx.doi.org/10.1002/sctm.18-0226] [PMID: 31045328]

[140]
Bu T, Li Z, Hou Y, et al. Exosome-mediated delivery of inflammation-responsive Il-10 mRNA for controlled atherosclerosis treatment. Theranostics  2021; 11(20): 9988-10000.
 [http://dx.doi.org/10.7150/thno.64229] [PMID: 34815799]

[141]
Mendt M, Kamerkar S, Sugimoto H, et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight  2018; 3(8): e99263.
 [http://dx.doi.org/10.1172/jci.insight.99263] [PMID: 29669940]

[142]
Guo D, Xu Y, Ding J, et al. Roles and clinical applications of exosomes in cardiovascular disease. BioMed Res Int  2020; 2020: 1-8.
 [http://dx.doi.org/10.1155/2020/5424281] [PMID: 32596327]

[143]
Katz MG, Swain JD, Tomasulo CE, Sumaroka M, Fargnoli A, Bridges CR. Current strategies for myocardial gene delivery. J Mol Cell Cardiol  2011; 50(5): 766-76.
 [http://dx.doi.org/10.1016/j.yjmcc.2010.09.003] [PMID: 20837022]

[144]
Ishikawa K, Tilemann L, Fish K, Hajjar RJ. Gene delivery methods in cardiac gene therapy. J Gene Med  2011; 13(10): 566-72.
 [http://dx.doi.org/10.1002/jgm.1609] [PMID: 21954037]

[145]
Vekstein AM, Wendell DC, DeLuca S, et al. Targeted delivery for cardiac regeneration: comparison of intra-coronary infusion and intra-myocardial injection in porcine hearts. Front Cardiovasc Med  2022; 9: 833335.
 [http://dx.doi.org/10.3389/fcvm.2022.833335] [PMID: 35224061]

[146]
Ylä-Herttuala S, Bridges C, Katz MG, Korpisalo P. Angiogenic gene therapy in cardiovascular diseases: Dream or vision? Eur Heart J  2017; 38(18): ehw547.
 [http://dx.doi.org/10.1093/eurheartj/ehw547] [PMID: 28073865]

[147]
Tilemann L, Ishikawa K, Weber T, Hajjar RJ. Gene therapy for heart failure. Circ Res  2012; 110(5): 777-93.
 [http://dx.doi.org/10.1161/CIRCRESAHA.111.252981] [PMID: 22383712]

[148]
Dib N, Khawaja H, Varner S, McCarthy M, Campbell A. Cell therapy for cardiovascular disease: A comparison of methods of delivery. J Cardiovasc Transl Res  2011; 4(2): 177-81.
 [http://dx.doi.org/10.1007/s12265-010-9253-z] [PMID: 21181320]

[149]
Cannatà A, Ali H, Sinagra G, Giacca M. Gene therapy for the heart lessons learned and future perspectives. Circ Res  2020; 126(10): 1394-414.
 [http://dx.doi.org/10.1161/CIRCRESAHA.120.315855] [PMID: 32379579]

[150]
Korpela H, Järveläinen N, Siimes S, et al. Gene therapy for ischaemic heart disease and heart failure. J Intern Med  2021; 290(3): 567-82.
 [http://dx.doi.org/10.1111/joim.13308] [PMID: 34033164]

[151]
Wolfram JA, Donahue JK. Gene therapy to treat cardiovascular disease. J Am Heart Assoc  2013; 2(4): e000119.
 [http://dx.doi.org/10.1161/JAHA.113.000119] [PMID: 23963752]

[152]
Katz MG, Fargnoli AS, Pritchette LA, Bridges CR. Gene delivery technologies for cardiac applications. Gene Ther  2012; 19(6): 659-69.
 [http://dx.doi.org/10.1038/gt.2012.11] [PMID: 22418063]

[153]
Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation  2009; 120(5): 366-75.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.108.834903] [PMID: 19620503]

[154]
Ladage D, Turnbull IC, Ishikawa K, et al. Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther  2011; 18(10): 979-85.
 [http://dx.doi.org/10.1038/gt.2011.52] [PMID: 21512506]

[155]
Ishikawa K, Weber T, Hajjar RJ. Human cardiac gene therapy. Circ Res  2018; 123(5): 601-13.
 [http://dx.doi.org/10.1161/CIRCRESAHA.118.311587] [PMID: 30355138]

[156]
Han S, Hwang C. Pericardial approach for cardiac therapies: Old practice with new ideas. Korean Circ J  2010; 40(10): 479-88.
 [http://dx.doi.org/10.4070/kcj.2010.40.10.479] [PMID: 21088750]

[157]
de Pedro MÁ, Pulido M, Marinaro F, et al. Intrapericardial administration of secretomes from menstrual blood-derived mesenchymal stromal cells: effects on immune-related genes in a porcine model of myocardial infarction. Biomedicines  2022; 10(5): 1117.
 [http://dx.doi.org/10.3390/biomedicines10051117] [PMID: 35625854]

[158]
Shazly T, Smith A, Uline MJ, Spinale FG. Therapeutic payload delivery to the myocardium: Evolving strategies and obstacles. JTCVS Open  2022; 10: 185-94.
 [http://dx.doi.org/10.1016/j.xjon.2022.04.043] [PMID: 36004211]

[159]
Tuma J, Fernández-Viña R, Carrasco A, et al. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J Transl Med  2011; 9(1): 183.
 [http://dx.doi.org/10.1186/1479-5876-9-183] [PMID: 22029669]

[160]
Hulot JS, Ishikawa K, Hajjar RJ. Gene therapy for the treatment of heart failure: Promise postponed. Eur Heart J  2016; 37(21): 1651-8.
 [http://dx.doi.org/10.1093/eurheartj/ehw019] [PMID: 26922809]

[161]
 Safri Z. Management of coronary artery disease. In IOP Conference Series: Earth and Environmental Science. IOP Publishing 2018; 125: p. 012125.

[162]
Ylä-Herttuala S, Baker AH. Cardiovascular gene therapy: Past, present, and future. Mol Ther  2017; 25(5): 1095-106.
 [http://dx.doi.org/10.1016/j.ymthe.2017.03.027] [PMID: 28389321]

[163]
Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: Biological context, challenges, prospects. Heart  2011; 97(3): 181-9.
 [http://dx.doi.org/10.1136/hrt.2009.180414] [PMID: 20884790]

[164]
Scimia MC, Gumpert AM, Koch WJ. Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther  2014; 14(2): 183-95.
 [http://dx.doi.org/10.1517/14712598.2014.866085] [PMID: 24328708]

[165]
Ylä-Herttuala S. Cardiovascular gene therapy with vascular endothelial growth factors. Gene  2013; 525(2): 217-9.
 [http://dx.doi.org/10.1016/j.gene.2013.03.051] [PMID: 23608170]

[166]

clinicaltrials.gov.  Available from: https://clinicaltrials.gov/search?locStr=United%20States&country=United%20States&distance=50&cond=Coronary%20Artery%20Disease&term=Coronary%20Heart%20Disease&intr=gene%20therapy (Accessed Sept 11, 2023).

[167]
Migliara G, Baccolini V, Rosso A, et al. Familial hypercholesterolemia: A systematic review of guidelines on genetic testing and patient management. Front Public Health  2017; 5: 252.
 [http://dx.doi.org/10.3389/fpubh.2017.00252] [PMID: 28993804]

[168]
Fu Q, Hu L, Shen T, Yang R, Jiang L. Recent advances in gene therapy for familial hypercholesterolemia: An update review. J Clin Med  2022; 11(22): 6773.
 [http://dx.doi.org/10.3390/jcm11226773] [PMID: 36431249]

[169]
Gold ME, Nanna MG, Doerfler SM, et al. Prevalence, treatment, and control of severe hyperlipidemia. Am J Prevent Cardiol  2020; 3: 100079.
 [http://dx.doi.org/10.1016/j.ajpc.2020.100079] [PMID: 34327462]

[170]
Huff MW, Assini JM, Hegele RA. Gene therapy for hypercholesterolemia: Sweet dreams and flying machines. Circ Res  2014; 115(6): 542-5.
 [http://dx.doi.org/10.1161/CIRCRESAHA.114.304800] [PMID: 25170090]

[171]
Tadin-Strapps M, Peterson LB, Cumiskey AM, et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res  2011; 52(6): 1084-97.
 [http://dx.doi.org/10.1194/jlr.M012872] [PMID: 21398511]

[172]
Gaudet D, Stroes ES, Méthot J, et al. Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Hum Gene Ther  2016; 27(11): 916-25.
 [http://dx.doi.org/10.1089/hum.2015.158] [PMID: 27412455]

[173]

clinicaltrials.gov.  Available from: https://clinicaltrials.gov/search?locStr=United%20States&country=United%20States&distance=50&cond=Hyperlipidemia&term=Familial%20Hypercholesterolemia&intr=gene%20therapy(Accessed Sept 11, 2023).

[174]
Eckhouse SR, Jones JA, Spinale FG. Gene targeting in ischemic heart disease and failure: Translational and clinical studies. Biochem Pharmacol  2013; 85(1): 1-11.
 [http://dx.doi.org/10.1016/j.bcp.2012.08.018] [PMID: 22935384]

[175]
Swedberg K. Heart failure subtypes: Pathophysiology and definitions. Diabetes Res Clin Pract  2021; 175: 108815.
 [http://dx.doi.org/10.1016/j.diabres.2021.108815] [PMID: 33862057]

[176]

clinicaltrials.gov.  Available from: https://clinicaltrials.gov/search?locStr=United%20States&country=United%20States&distance=50&cond=Heart%20Failure&term=Cardiovascular%20Diseases&intr=gene%20therapy (Accessed Sept 11, 2023).

[177]
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update: A report from the american heart association. circulation  2014; 129(3): 28-92.

[178]
Bezzerides VJ, Prondzynski M, Carrier L, Pu WT. Gene therapy for inherited arrhythmias. Cardiovasc Res  2020; 116(9): 1635-50.
 [http://dx.doi.org/10.1093/cvr/cvaa107] [PMID: 32321160]

[179]
Bongianino R, Priori SG. Gene therapy to treat cardiac arrhythmias. Nat Rev Cardiol  2015; 12(9): 531-46.
 [http://dx.doi.org/10.1038/nrcardio.2015.61] [PMID: 25917154]

[180]

clinicaltrials.gov.  Available from: https://clinicaltrials.gov/search?locStr=United%20States&country=United%20States&distance=50&cond=Cardiac%20Arrhythmia&term=Arrhythmogenic%20Cardiomyopathy&intr=gene%20therapy (Accessed Sept 11, 2023).

[181]
Musunuru K. How genome editing could be used in the treatment of cardiovascular diseases. Per Med  2018; 15(2): 67-9.
 [http://dx.doi.org/10.2217/pme-2017-0078] [PMID: 29714123]

[182]
Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR–Cas13. Nature  2017; 550(7675): 280-4.
 [http://dx.doi.org/10.1038/nature24049] [PMID: 28976959]

[183]
Merkle T, Merz S, Reautschnig P, et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat Biotechnol  2019; 37(2): 133-8.
 [http://dx.doi.org/10.1038/s41587-019-0013-6] [PMID: 30692694]

[184]
Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos. Nature  2017; 548(7668): 413-9.
 [http://dx.doi.org/10.1038/nature23305] [PMID: 28783728]

[185]
Friedmann T. Genetic therapies, human genetic enhancement, and … eugenics? Gene Ther  2019; 26(9): 351-3.
 [http://dx.doi.org/10.1038/s41434-019-0088-1] [PMID: 31273325]

[186]
National academies of sciences, engineering, and medicine. Human Genome Editing: Science Ethics, and Governance. National Academies Press 2017.

[187]
German DM, Mitalipov S, Mishra A, Kaul S. Therapeutic genome editing in cardiovascular diseases. JACC Basic Transl Sci  2019; 4(1): 122-31.
 [http://dx.doi.org/10.1016/j.jacbts.2018.11.004] [PMID: 30847427]

[188]
Evans JH. Setting ethical limits on human gene editing after the fall of the somatic/germline barrier. Proc Natl Acad Sci  2021; 118(22): e2004837117.
 [http://dx.doi.org/10.1073/pnas.2004837117] [PMID: 34050016]

[189]
Rossant J. Gene editing in human development: Ethical concerns and practical applications. Development  2018; 145(16): dev150888.
 [http://dx.doi.org/10.1242/dev.150888] [PMID: 30045910]

[190]
Gumer JM. The wisdom of germline editing: An ethical analysis of the use of CRISPR-Cas9 to edit human embryos. New Bioeth  2019; 25(2): 137-52.
 [http://dx.doi.org/10.1080/20502877.2019.1606151] [PMID: 31130112]

[191]
Ansah EO. Ethical challenges and controversies in the practice and advancement of gene therapy. Adv Cell Gene Ther  2022; 2022: 1-5.
 [http://dx.doi.org/10.1155/2022/1015996]

[192]
Nishiga M, Qi LS, Wu JC. Therapeutic genome editing in cardiovascular diseases. Adv Drug Deliv Rev  2021; 168: 147-57.
 [http://dx.doi.org/10.1016/j.addr.2020.02.003] [PMID: 32092381]
Cite As
Current Gene Therapy

Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders

Abstract

Graphical Abstract
